Seagen's Adcetris/Immunotherapy Combo Achieves 98% Overall Response Rate in Early-Stage Lymphoma Setting
Portfolio Pulse from Vandana Singh
Seagen Inc announced updated efficacy and safety results from Part C of a phase 2 single-arm trial of Adcetris combined with nivolumab and standard chemotherapy agents for the frontline treatment of patients with early-stage classical Hodgkin lymphoma. The trial achieved a 98% overall response rate and a 93% complete response rate at the end of treatment.
June 13, 2023 | 1:37 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Seagen's Adcetris/Immunotherapy combo achieves 98% overall response rate in early-stage lymphoma setting, potentially boosting the company's market position.
The positive results from the phase 2 trial of Adcetris combined with nivolumab and standard chemotherapy agents for the frontline treatment of patients with early-stage classical Hodgkin lymphoma indicate a potential increase in demand for the treatment. This could lead to increased revenues for Seagen and a positive impact on its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Takeda Pharmaceutical has commercialization rights for Adcetris in Europe, and the positive trial results may lead to increased demand for the treatment.
As Takeda Pharmaceutical has commercialization rights for Adcetris in Europe, the positive results from the phase 2 trial may lead to increased demand for the treatment in the European market. This could result in increased revenues for Takeda and a positive impact on its stock price in the short term.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 60